Based on the idea that IDH1 mutations can alter the 5-ALA metabolic pathway and stimulate exogenous 5-ALA fluorescence, we confirmed an association between the R132H IDH1 mutation and enhanced 5-ALA fluorescence in WHO grade III gliomas, then investigated metabolic aspects of the underlying mechanism. This evidence concerns the gene IDH1 and central nervous system cancer.